Handa Pharmaceuticals (Taiwan) Today
Handa Pharmaceuticals is selling for under 78.90 as of the 31st of January 2025; that is 0.77% up since the beginning of the trading day. The stock's lowest day price was 77.7. The performance scores are derived for the period starting the 11th of February 2023 and ending today, the 31st of January 2025. Click here to learn more.
Valuation
Check how we calculate scores
Handa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Handa Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Handa Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Handa Pharmaceuticals (6620) is traded on Taiwan OTC Exchange in Taiwan and employs 9 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Handa Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Handa Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Handa Pharmaceuticals operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 115.57 M outstanding shares.
Handa Pharmaceuticals has accumulated about 315.09 M in cash with (308.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.72.
Check Handa Pharmaceuticals Probability Of Bankruptcy
Handa Pharmaceuticals Risk Profiles
Although Handa Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Handa Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.75 | |||
| Semi Deviation | 2.5 | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.55 |
Handa Stock Against Markets
Handa Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Handa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Handa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Handa Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Handa Pharmaceuticals Corporate Management
Elected by the shareholders, the Handa Pharmaceuticals' board of directors comprises two types of representatives: Handa Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Handa. The board's role is to monitor Handa Pharmaceuticals' management team and ensure that shareholders' interests are well served. Handa Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Handa Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weili Lin | Independent Director | Profile | |
| Meifang Zhang | Director | Profile | |
| Guiqing Wang | Independent Director | Profile | |
| Fangyu Liu | Chairman of the Board | Profile | |
| Xinyu Chen | Deputy General Manager-Finance | Profile | |
| Junliang Chen | General Manager, Director | Profile |
Additional Tools for Handa Stock Analysis
When running Handa Pharmaceuticals' price analysis, check to measure Handa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Handa Pharmaceuticals is operating at the current time. Most of Handa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Handa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Handa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Handa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.